Characteristically guanethidine produced early morning postural hypotensive symptoms, whereas hypotensive symptoms caused by bethanidine and debrisoquine occurred at other times of the day and particularly one to two hours after tablet ingestion.
Symptoms due to orthostatic and exertional hypotension occurred in 23.4 per cent of 448 hypertensive patients treated with guanethidine, debrisoquine, or bethanidine. Symptoms were significantly more frequent in patients treated with guanethidine than in those treated with bethanidine or debrisoquine.
Women rather than men and patients with radiological evidence of cardiomegaly, electrocardiographic evidence of left ventricular hypertrophy, or STIT wave changes, developed these symptoms signifcantly more often than other patients. A raised blood urea was found more frequently in patients with postural hypotensive symptoms.
Characteristically guanethidine produced early morning postural hypotensive symptoms, whereas hypotensive symptoms caused by bethanidine and debrisoquine occurred at other times of the day and particularly one to two hours after tablet ingestion.
Debrisoquine andguanethidine had a significantly greater negative chronotropic effect than bethanidine. It is suggested that negative chronotropic effects of these drugs may potentiate hypotensive symptoms in patients with cardiovascular, renal, or cerebrovascular disease. It should be possible to minimize symptoms of postural hypotension by attention to predisposing factors and selection of treatment accordingly.
Treatment of hypertension with post-ganglionic sympathetic blocking drugs produces hypotension related to posture: this is both an inevitable consequence of their mode of action and a possible cause of troublesome side effects. In mild cases other drugs without orthostatic effects may be used, but treatment with post-ganglionic sympathetic blocking drugs may be essential for more severe hypertension, and debrisoquine, bethanidine, and guanethidine are the drugs most frequently employed. Debrisoquine and bethanidine are said to produce fewer orthostatic symptoms than guanethidine (Bath, Pickering, and Turner, I967; Kitchin and Turner, I966 Only symptoms and blood pressure levels found at least 6 months after the initiation of therapy were recorded. Any patients in whom symptoms were thought to be caused by inappropriate timing of doses or excessive therapy were not included in the survey unless symptoms persisted after appropriate dose readjustments.
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The age, height, weight, and blood pressure levels of each patient before and after treatment with debrisoquine, guanethidine, or bethanidine were recorded as well as the initial blood urea, the heart rate from the electrocardiogram, and electrocardiographic criteria of left ventricular hypertrophy (Sokolow and Lyon, I949) . ST/T wave changes were coded according to the revised Minnesota Code (Rose and Blackburn, I968) . Radiological evidence of cardiomegaly was defined as a cardiothoracic ratio of >I:2. Dizziness was described as mild if it was recorded on at least three occasions after the first 6 months of treatment, but had disappeared by the date of the study; moderate if it had persisted up to this time; severe if it had been recorded on at least 6 occasions or blackouts had occurred; and disabling if treatment had had to be changed on its account.
From the last clinic review the lying and standing blood pressure levels and the heart rates were recorded, and also the blood urea, electrocardiographic changes, and the radiological heart size.
Results
There were 448 patients treated with post-ganglionic sympathetic blocking drugs; 205 were taking guanethidine, I58 bethanidine, and 85 debrisoquine.
Results for patients with postural symptoms of different severity have been amalgamated for ease of presentation. For each drug patients have been divided into those with symptoms of postural hypotension and those without such symptoms. There were no significant differences in the mean supine and standing blood pressure levels and the average age and weight between these groups of patients before treatment (Table i) .
The mean heart rates of all groups were similar before treatment but afterwards there were significant differences. Debrisoquine and guanethidine slowed the resting heart rate by i6 per cent but bethanidine only slowed the heart rate by 5.6 per cent (P < o.oi). There were parallel effects on the standing heart rates, which for all groups were slightly higher than the supine heart rates.
Evidence of vascular and renal disease was significantly more frequent in all the symptomatic groups (P < o.oi). Cardiomegaly and electrocardiographic evidence of left ventricular hypertrophy were more often present in the symptomatic groups (P < o.oi). ST/T wave changes were more frequent in the patients with postural hypotensive symptoms, and pretreatment blood urea was significantly higher in this group (P < o.oi). After treatment symptomatic patients showed significantly greater rises of the blood urea and more frequent electrocardiographic evidence of left ventricular hypertrophy and radiographic evidence of cardiomegaly (P < o.oi). Women had postural symptoms relatively more frequently than men (P < 0.02) ( Table 2) .
No permanent complications of postural hypotension were detected. Angina frequently occurred in patients who also complained of postural symptoms (36, 34%), but angina rarely occurred at the same time as the hypotensive symptoms even if these occurred on exertion. However, in some patients before admission to the study it was noted that severe hypotensive episodes caused by inappropriate dose of drug were sometimes associated Predisposition to postural hypotensive symptoms Io6I I4 * Significant differences between the total group with symptoms and the group without symptoms using grouped 't' test (P<o.oi).
t Significant differences between the total group with symptoms and the group without symptoms (using x2 test, P < O.OI). t Significant differences between the total group with symptoms and the group without symptoms (using X2 test, P < 0.02).
Percentages are in parentheses.
Conversion factor from SI units to Traditional units: blood urea I mmol/l 6 mg/Iooml.
with angina and then hypotension and angina could be relieved by altering the medication. There were differences between the drugs taken and the frequency of certain symptoms. Exertional hypotension was less frequent and less severe with bethanidine than with guanethidine, but unexpected diurnal or nocturnal orthostatic symptoms with bethanidine were significantly more frequent than in those taking guanethidine or debrisoquine (P < 0.02) ( Table 3 ).
Other differences did not attain statistical significance but bethanidine and debrisoquine rarely caused early morming hypotension if the medication was taken correctly; many patients, however, took their second dose of debrisoquine after 4.0 p.m. and readjustment was necessary. Patients on bethanidine Spreading the quantity of any drug over more than the recommended number of doses did not appear to relieve the patients' symptoms. A change of treatment from one post-ganglionic blocking drug to another because of postural symptoms was rarely beneficial, though this often altered the time of onset and type of symptoms. However, 6 patients on guanethidine had fewer symptoms when changed to debrisoquine.
Discussion
In this study, the groups of patients taking each of the three drugs were comparable as far as pretreatment blood pressure levels and resting heart rate were concerned. They remained comparable when their mean post-treatment blood pressure levels, both lying and standing, were considered. The average pulse pressure was slightly lower in the group with postural symptoms. However, from the results of this study there is no evidence that postural hypotensive symptoms are just a reflection of a greater reduction of standing blood pressure in the affected group. Additional therapy consisted only of diuretics which were given to a similar proportion in each group (65%) and which would not account for the differences in symptoms. The different durations of treatment with each of the post-ganglionic sympathetic blocking drugs reflect the date of the introduction of the drug in the clinic, and though there are differences between drug groups there are no differences within each group.
However, when comparing asymptomatic with symptomatic patients in all three drug groups, the latter more often showed electrocardiographic evidence ofleft ventricular hypertrophy and ST/T wave changes and had radiological evidence of cardiomegaly. The renal status of symptomatic patients as judged by blood urea was worse. Women complained of symptoms proportionately more often than men. Patients with symptoms were older on average (though not significantly) than the asymptomatic patients. After treatment, certain differences persisted. There was less frequent improvement and more frequent deterioration in renal and cardiovascular parameters in symptomatic than asymptomatic patients. In the presence of a blood urea exceeding i6.6 mmol/l (ioo mg/Ioo ml), there was often severe postural hypotension, particularly when guanethidine was the principal antihypertensive drug.
In comparison, during the same period of observation, other patients in the clinic treated with alpha-methyldopa, reserpine, diuretics, and/or betareceptor blocking drugs were examined, but less than 5 per cent had postural symptoms. Alphamethyldopa and reserpine (less than o.3 mg per day) had negligible effects on the heart rate.
Differences were also apparent between drug groups. More patients taking guanethidine (29%) were affected by postural symptoms than was previously suggested (Leishman and Sandler, I967) , whereas debrisoquine and bethanidine produced fewer severe side effects (I8% and I9%, respectively). These figures may reflect either the differing kinetic properties of the drugs themselves or differences in their mode of action.
Guanethidine has the longest half-life of the three compounds, has a prolonged effect, and exerts a significant action in the early morning when hypotensive symptoms commonly occur. This effect might be potentiated by an early morning reduction in vascular volume (Cranston and Brown, I963) or by an inhibitory effect of guanethidine on the diurnal rhythm of catecholamine excretion (Vyshnepolski, I969).
Bethanidine is more rapidly absorbed and excreted (Doyle and Morley, I965) , causes a less smooth control of blood pressure throughout the day, and in this study often generated hypotensive symptoms between one or two hours after a dose. Debrisoquine was less prone to these drawbacks.
Pharmacodynamic factors may also be involved in the differences between the groups. Guanethidine depletes tissues of catecholamines and has negative inotropic effects (Richardson et al., I960; Gaffney, Braunwald, and Cooper, I962; Kahler, Gaffney, and Braunwald, I962) . Debrisoquine and bethanidine do not deplete catecholamines significantly (Moe et al., I964; Boura and Green, I963) . Guanethidine is known to produce negative chronotropic effects but the effect of debrisoquine on the heart rate of hypotensive subjects is undocumented. The results presented here (Table i) suggest that debrisoquine has a similar effect to that of guanethidine, but that bethanidine is less potent in this respect. These effects may be caused by blocking of beta-receptors (Kaldor and Juvancz, I969) , but they may also result from direct depression of pacemaker activity as has been shown for both reserpine and guanethidine (Innes, Krayer, and Waud, I958 
